Pretransplant identification of acute rejection risk following kidney transplantation

Transplant International

Volumn 27, Issue 2, 2014, Pages 129-138

  Lebranchu, Yvon ^a   Baan, Carla ^b   Biancone, Luigi ^c   Legendre, Christophe ^d   Morales, José Maria ^e   Naesens, Maarten ^f   Thomusch, Oliver ^g   Friend, Peter ^h  

^a UNIVERSITÉ DE TOURS   (France)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

acute rejection; donor; high risk; immunological; recipient; risk factors

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PANEL REACTIVE ANTIBODY;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; CLINICAL TRIAL (TOPIC); COLD ISCHEMIA; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DONOR SELECTION; END STAGE RENAL DISEASE; ETHNICITY; GRAFT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICATION COMPLIANCE; MEMORY T LYMPHOCYTE; META ANALYSIS (TOPIC); OBESITY; PATIENT HISTORY OF KIDNEY TRANSPLANTATION; PERIPHERAL VASCULAR DISEASE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

ACUTE REJECTION; DONOR; HIGH RISK; IMMUNOLOGICAL; RECIPIENT; RISK FACTORS;

AFRICAN AMERICANS; BODY MASS INDEX; COLD TEMPERATURE; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISCHEMIA; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; RISK FACTORS; TIME FACTORS;

EID: 84892368518     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12205     Document Type: Review

References (76)

1. United States Renal Data System (USRDS) Annual Report 2012. Available at http://www.usrds.org/adr.aspx
2. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
3. Cole EH, Johnston O, Rose CL, Gill JS,. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3: 814.
4. Dunn TB, Noreen H, Gillingham K, et al,. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132.
5. Kuo H-T, Sampaio MS, Vincenti F, Bunnapradist S,. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010; 56: 1127.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1.
7. European Medicines Agency. Guideline on clinical investigation of immunosuppressants for solid organ transplantation (2008). CHMP/EWP/263148/06 Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003593.pdf
8. Hanaway MJ, Woodle ES, Mulgaonkar S, et al,. INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
9. Van Gelder T, Tedesco Silva H, de Fijter JW, et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 2010; 89: 595.
10. Nöel C, Abramowicz D, Durand D, et al,. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20: 1385.
11. Kim MJ, Tsinalis D, Franz S, et al,. ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial. Ann Transplant 2008; 13: 21.
12. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D,; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. New Engl J Med 2006; 355: 1967.
13. Øien CM, Reisaeter AV, Leivestad T, Dekker FW, Line PD, Os I,. Living donor kidney transplantation: the effects of donor age and gender on short- and long-term outcomes. Transplantation 2007; 83: 600.
14. Quiroga I, McShane P, Koo DD, et al,. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transpl 2006; 21: 1689.
15. Gore JL, Pham PT, Danovitch GM, et al,. Obesity and outcome following renal transplantation. Am J Transplant 2006; 6: 357.
16. Pallardõ Mateu LM, Sancho Calabuig A, Capdevila Plaza L, Franco Esteve A,. Acute rejection and late renal transplant failure: risk factors and prognosis. Nephrol Dial Transplant 2004; 19 (Suppl): iii38.
17. Mota A, Figueiredo A, Cunha MF, Bastos M, Pratas J, Furtado L,. Risk factors for acute rejection in 806 cyclosporine-treated renal transplants: a multivariate analysis. Transplant Proc 2003; 35: 1061.
18. Sagedal S, Nordal KP, Hartmann A, et al,. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
19. Boom H, Mallat MJ, de Fijter JW, Zwinderman AH, Paul LC,. Delayed graft function influences renal function, but not survival. Kidney Int 2000; 58: 859.
20. de Fitjter JW,. The impact of age on rejection in kidney transplantation. Drugs Aging 2005; 22: 433.
21. Schold JD, Srinivas TR, Braun WE, Shoskes DA, Nurko S, Poggio ED,. The relative risk of overall graft loss and acute rejection among African American renal transplant recipients is attenuated with advancing age. Clin Transplant 2011; 25: 721.
22. Prendergast MB, Gaston RS,. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol 2010; 5: 1305.
23. Trébern-Launay K, Foucher Y, Giral M, et al,. Poor long-term outcome in second kidney transplantation: a delayed event. PLoS ONE 2012; 7: e47915.
24. Sanfilippo F, Vaughn WK, LeFor WM, Spees EK,. Multivariate analysis of risk factors in cadaver donor kidney transplantation. Transplantation 1986; 42: 28.
25. Dharnidharka VR, Cherikh WS, Neff R, Cheng Y, Abbott KC,. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant 2010; 10: 1312.
26. Gatault P, Halimi JM, Forconi C, et al,. CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction. Am J Transplant 2013; 13: 2119.
27. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL,. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15: 1633.
28. Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW,. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006; 81: 1658.
29. Landin L, Rodriguez-Perez JC, Garcia-Bello MA, et al,. Kidney transplants in HIV-positive recipients under HAART. A comprehensive review and meta-analysis of 12 series. Nephrol Dial Transplant 2010; 25: 3106.
30. Malat GE, Ranganna KM, Sikalas N, Liu L, Jindal RM, Doyle A,. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial. Transplantation 2012; 94: 1020.
31. Mazuecos A, Fernandez A, Andres A, et al,. HIV infection and renal transplantation. Nephrol Dial Transplant 2011; 26: 1401.
32. Stock PG, Barin B, Murphy B, et al,. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 2004.
33. Frassetto LA, Tan-Tam C, Stock PG,. Renal transplantation in patients with HIV. Nat Rev Nephrol 2009; 5: 582.
34. Pedroso S, Martins L, Fonseca I, et al,. Impact of hepatitis C virus on renal transplantation: association with poor survival. Transplant Proc 2006; 38: 1890.
35. Brown KL, El-Amm JM, Doshi MD, et al,. Intermediate-term outcomes of hepatitis C-positive compared with hepatitis C-negative deceased-donor renal allograft recipients. Am J Surg 2008; 195: 298.
36. Singh N, Neidlinger N, Djamali A, et al,. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant 2012; 26: 684.
37. Morales JM, Marcén R, Andres A, et al,. Renal transplantation in patients with hepatitis C antibody. A long national experience. NDT Plus 2010; 3 (Suppl. 2): ii41.
38. Andree H, Nickel P, Nasiadko C, et al,. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006; 17: 573.
39. Vincenti F, Dritselis A, Kirkpatrick P,. Belatacept. Nat Rev Drug Discov 2011; 10: 655.
40. Süsal C, Döhler B, Sadeghi M, Ovens J, Opelz G,. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a Collaborative Transplant Study report. Transplantation 2009; 87: 1367.
41. Mohan S, Palanisamy A, Tsapepas D, et al,. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23: 2061.
42. Burns JM, Cornell LD, Perry DK, et al,. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
43. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
44. Dominigues EM, Matuck T, Graciano ML, et al,. Panel reactive HLA antibodies, soluble CD30 level, and acute rejection six months following renal transplant. Clin Transplant 2010; 24: 821.
45. Lee KW, Kim SJ, Lee DS, et al,. Effect of panel-reactive antibody positivity on graft rejection before or after kidney transplantation. Transplant Proc 2004; 36: 2009.
46. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G,. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293.
47. Sánchez-Zapardiel E, Castro-Panete MJ, Castillo-Rama M, et al,. Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period. Transplantation 2013; 96: 70.
48. Sawitzki B, Schlickeiser S, Reinke P, Volk HD,. Pretransplant immune risk assessment. Current Opin Organ Transplant 2009; 14: 650.
49. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al,. Pre-transplant frequency of donor-specific, interferon gamma producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of post-transplant rejection episodes. J Immunol 1999; 163: 2267.
50. Hricik DE, Poggio ED, Woodside KJ, et al,. Effects of cellular sensitization and donor age on acute rejection and graft function after deceased-donor kidney transplantation. Transplantation 2013; 95: 1254.
51. Bestard O, Crespo E, Stein M, et al,. Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant 2013; 13: 1880.
52. Ashoor I, Najafian N, Korin Y, et al,. Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 2013; 13: 1871.
53. Organ Procurement and Transplant Network Annual Data Report 2011. Available at http://optn.transplant.hrsa.gov/news/newsDetail.asp?id=1589.
54. Ahmad N, Ahmed K, Khan MS, et al,. Living-unrelated donor renal transplantation: an alternative to living-related donor transplantation? Ann R Coll Surg Engl 2008; 90: 247.
55. Chkhotua AB, Klein T, Shabtai E, et al,. Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols. Urology 2003; 62: 1002.
56. Tullius SG, Tran H, Guleria I, Malek SK, Tilney NL, Milford E,. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg 2010; 252: 662.
57. De Fijter J, Mallat MJ, Doxiadis II, et al,. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12: 1538.
58. Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DR,. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007; 7: 2114.
59. Diet C, Audard V, Roudot-Thoraval F, Matignon M, Lang P, Grimbert P,. Immunological risk in recipients of kidney transplants from extended criteria donors. Nephrol Dial Transplant 2010; 25: 2745.
60. Saidi RF, Elias N, Kawai T, et al,. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant 2007; 12: 2769.
61. Sánchez-Fructuoso AI, Prats D, Marques M, et al,. Does donor brain death influence acute vascular rejection in the kidney transplant? Transplantation 2004; 78: 142.
62. Tan JC, Kim JP, Chertow GM, Grumet FC, Desai M,. Donor-recipient sex mismatch in kidney transplantation. Gend Med 2012; 9: 335.
63. Ferrari P, Lim W, Dent H, McDonald SP,. Effect of donor-recipient age difference on graft function and survival in live-donor kidney transplantation. Nephrol Dial Transplant 2011; 26: 702.
64. Alonso A, Fernández-Rivera C, Villaverde P, et al,. Renal transplantation from non-heart-beating donors: a single-center 10-year experience. Transplant Proc 2005; 37: 3658.
65. Sudhindran S, Pettigrew GJ, Drain A, et al,. Outcome of transplantation using kidneys from controlled (Maastricht category 3) non-heart-beating donors. Clin Transplant 2003; 17: 93.
66. Barlow AD, Metcalfe MS, Johari Y, Elwell R, Veitch PS, Nicholson ML,. Case-matched comparison of long-term results of non-heart beating and heart-beating donor renal transplants. Br J Surg 2009; 96: 685.
67. Wells AC, Rushworth L, Thiru S, et al,. Donor kidney disease and transplant outcome for kidneys donated after cardiac death. Br J Surg 2009; 96: 299.
68. Summers DM, Johnson RJ, Allen J, et al,. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. Lancet 2010; 376: 1303.
69. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA,. Effect of donor age and cold storage time on outcome in recipients of kidneys donated after circulatory death in the UK: a cohort study. Lancet 2013; 381: 727.
70. Gratwohl A, Döhler B, Stern M, Opelz G,. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet 2008; 372: 49.
71. Kim SJ, Gill JS,. H-Y incompatibility predicts short-term outcomes for kidney transplant recipients. J Am Soc Nephrol 2009; 20: 2025.
72. Jayaram D, Kommareddi M, Sung RS, Luan FL,. Delayed graft function requiring more than one-time dialysis treatment is associated with inferior clinical outcomes. Clin Transplant 2012; 26: E536.
73. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR,. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 1039.
74. Parekh J, Bostrom A, Feng S,. Diabetes mellitus: a risk factor for delayed graft function after deceased donor kidney transplantation. Am J Transplant 2010; 10: 298.
75. Jamieson RW, Friend PJ,. Organ reperfusion and preservation. Front Biosci 2008; 13: 221.
76. Irish WD, Ilsley JN, Schnitzler MA, Feng S, Brennan DC,. A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant 2010; 10: 2279.